ArticleThe Lancet. Rheumatology2022

Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study.

Satveer K Mahil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.